Brief: Biophytis: Promising Full Results From Sara-Interest Phase 2B Trial Of Sarconeos (BIO101)

Biophytis SA

04/10/2021 07:19

Oct 4 (Reuters) - Biophytis SA  ALBPS.PA :
    * BIOPHYTIS ANNOUNCES PROMISING FULL RESULTS FROM THE
SARA-INTEREST PHASE 2B TRIAL OF SARCONEOS (BIO101) IN SARCOPENIA
AT THE 11TH ANNUAL INTERNATIONAL CONFERENCE ON FRAILTY AND
SARCOPENIA RESEARCH (ICFSR) SEPTEMBER 29 – OCTOBER 2, 2021
    * SARCONEOS (BIO101) AT HIGHEST DOSE (350 MG BID) SHOWED A
CLINICALLY MEANINGFUL IMPROVEMENT IN 400-METER WALK TEST
(400MWT), PRIMARY ENDPOINT OF STUDY, INCLUDING IN
SUB-POPULATIONS AT HIGHER RISK OF MOBILITY DISABILITY, AFTER 6
MONTHS OF TREATMENT
    * BIOPHYTIS IS PREPARING TO START A PHASE 3 PROGRAM WITH
SARCONEOS
(BIO101) AT HIGHEST DOSE (350 MG BID) IN 2022, TARGETING SIMILAR
POPULATION AND ENDPOINTS

Source text for Eikon:  ID:nGNX1gFtPF 
Further company coverage:  ALBPS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))